| *Sponsored
Low Float (NYSE American: MAIA) Paints Pre-Market Green With A Strong Surge
January 13th Dear Reader,
MAIA Biotechnology, Inc. (NYSE American: MAIA) is making green moves this morning ahead of the bell.
Here's a few quick notes:
#1. This is a low float idea with fewer than 20Mn shares.
#2. Two analyst targets are suggesting triple-digit potential upside (find report links below).
#3. Last week's strong news regarding a clinical supply agreement may have largely flown under the radar.
Take a moment to review my initial report and then consider (NYSE American: MAIA) for a top watchlist position. -----
Even though a cold front ripped through the U.S. last week, things started heating up Friday morning.
My latest alert, a Nasdaq Biopharma profile, was brought to your attention after closing Wednesday night in after hours at $1.1882.
Running to a pre-market high of $2.26 on Friday, that breakout idea surged approximately 90% before the morning bell popped.
But it wasn't done there.
It made double-digit intraday swings on multiple occasions throughout the day.
At the same time, I caught wind of a past champ stacked with breakout potential once again.
Why? Analyst targets (2 separate ones) are painting a picture of a current chart valuation in undervalued territory.
In fact, from Friday's close, one target is providing upside potential of over 400% while another suggests 500+%!
Best part? This isn't the first time I've alerted this profile.
When I brought this one to your attention last, it erupted, running approximately 275+% in a few month span.
Based on some explosive new potential catalysts, and a few old ones, this past champ is back on my watchlist right now:
*MAIA Biotechnology, Inc. (NYSE American: MAIA)*
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out:
#1. One Analyst's Target Suggests Over 500% Potential Upside From MAIA's Current Chart Levels.
#2. Another Analyst Weighs In (Diamond Equity Research Report Suggests $11.25 Target).
#3. Volatility Could Be In Full Force Based On MAIA's Low Float.
#4. MAIA Biotechnology Announces Clinical Supply Agreement With BeiGene For Upcoming Phase 2 Trials In Three Cancer Indications.
#5. MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation For THIO As A Treatment For Pediatric High-Grade Gliomas.
But more on those in a second...
MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO
THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development.
Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase.
A New Therapeutic Strategy
THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death.
Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment.
These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020).
Clinical Development
MAIA is currently advancing THIO in a Phase 2 clinical study in Non-Small Cell Lung Cancer (NSCLC). This is the first study to test THIO’s immune system activation followed by administration of the checkpoint inhibitor cemiplimab, allowing for the immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that lower doses of THIO administered prior to Libtayo treatment would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progressed after first-line treatment with a checkpoint inhibitor.
THIO followed by Libtayo for the treatment of advanced non-small cell lung cancer is in clinical development, and the safety and efficacy of THIO or its administration with Libtayo have not been reviewed yet by any regulatory authorities.
Second-Generation
Telomere Targeting Agents
MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. This program may also allow us to strengthen their patent portfolio. Although the program is in early stages and they may not be able to identify suitable compounds, they believe they will be able to create a second generation of THIO-like compounds.
Their current second-generation pipeline of potential telomere-targeting agents includes five compounds that have successfully undergone in vitro inhibitory testing in five cancer models. The data from those studies showed a significantly lower 50% inhibitory concentration (IC50) for those compounds compared to THIO.
MAIA's Pipeline
The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: | 
Tidak ada komentar:
Posting Komentar